B. Riley Wealth Advisors Inc. Has $2.26 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

B. Riley Wealth Advisors Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,915 shares of the biopharmaceutical company’s stock after selling 604 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $2,261,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of GILD. Leo Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $2,743,000. MONECO Advisors LLC lifted its stake in shares of Gilead Sciences by 12.3% in the 4th quarter. MONECO Advisors LLC now owns 6,317 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 691 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $253,000. Rovin Capital UT ADV lifted its stake in shares of Gilead Sciences by 30.9% in the 4th quarter. Rovin Capital UT ADV now owns 7,473 shares of the biopharmaceutical company’s stock valued at $605,000 after purchasing an additional 1,765 shares during the period. Finally, Spartan Planning & Wealth Management acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $193,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Oppenheimer restated an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. TD Cowen lowered their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, April 26th. UBS Group lowered their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus price target of $83.69.

Gilead Sciences Price Performance

GILD stock opened at $63.15 on Wednesday. The stock has a 50-day moving average price of $65.79 and a two-hundred day moving average price of $73.13. The stock has a market cap of $78.68 billion, a PE ratio of 175.42, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.37 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.88%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.